Zeltia Group: Report at 31 March 2005
Madrid (ots/PRNewswire)
PharmaMar:
- Zalypsis: this is PharmaMar's fifth compound to reach clinical development.
- Aplidin: commenced Phase II studies on prostate and bladder cancer.
- Yondelis: pivotal Phase III studies commenced on ovarian cancer patients.
NeuroPharma:
- Presented pre-clinical data at the 7th International Conference on Alzheimer's and Parkinson's Disease.
Other:
- Investment in R&D amounted to 8.9 million euro in the first quarter.
- Group short- and long-term debt was similar to December 2004.
- Net cash consumption was 3.8 million euro in the first quarter.
Contact:
Isabel Lozano, CEO, PHARMAMAR, S.A., C/ Reyes, 1.Colmenar Viejo,
Madrid, Telephone +34-91-846-60-00; Catherine Moukheibir, Head of
Capital Market Strategy, ZELTIA, S.A., José Abascal, 2. Madrid,
Telephone +34-91-444-45-00; Ma. Luisa de Francia, CFO, ZELTIA, S.A.,
José Abascal, 2. Madrid, Telephone +34-91-444-45-00